Free Trial

Brokerages Set Galapagos NV (NASDAQ:GLPG) Price Target at $31.00

Galapagos logo with Medical background

Galapagos NV (NASDAQ:GLPG - Get Free Report) has been assigned a consensus rating of "Reduce" from the five brokerages that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation and four have issued a hold recommendation on the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $31.00.

GLPG has been the topic of several recent analyst reports. Raymond James downgraded Galapagos from an "outperform" rating to a "market perform" rating in a research note on Friday, August 2nd. Leerink Partnrs raised shares of Galapagos to a "hold" rating in a report on Monday, September 9th. Finally, Leerink Partners initiated coverage on shares of Galapagos in a research report on Monday, September 9th. They issued a "market perform" rating and a $24.00 target price for the company.

Check Out Our Latest Stock Analysis on GLPG

Galapagos Stock Performance

Shares of GLPG traded up $0.05 during mid-day trading on Wednesday, reaching $28.59. 78,781 shares of the company's stock traded hands, compared to its average volume of 132,099. The business's 50-day moving average price is $29.12 and its 200-day moving average price is $27.75. Galapagos has a 12 month low of $24.16 and a 12 month high of $42.46.

Institutional Trading of Galapagos

Several institutional investors have recently modified their holdings of GLPG. BNP Paribas Financial Markets raised its position in Galapagos by 783.6% in the first quarter. BNP Paribas Financial Markets now owns 5,328 shares of the biotechnology company's stock worth $172,000 after acquiring an additional 4,725 shares in the last quarter. Headlands Technologies LLC raised its holdings in shares of Galapagos by 949.3% in the 1st quarter. Headlands Technologies LLC now owns 787 shares of the biotechnology company's stock worth $25,000 after purchasing an additional 712 shares in the last quarter. Monaco Asset Management SAM lifted its stake in Galapagos by 148.3% during the first quarter. Monaco Asset Management SAM now owns 16,744 shares of the biotechnology company's stock valued at $539,000 after purchasing an additional 10,000 shares during the last quarter. Acadian Asset Management LLC boosted its holdings in Galapagos by 18.5% during the first quarter. Acadian Asset Management LLC now owns 15,186 shares of the biotechnology company's stock worth $488,000 after buying an additional 2,366 shares in the last quarter. Finally, AlphaCentric Advisors LLC grew its holdings in shares of Galapagos by 3.3% in the 2nd quarter. AlphaCentric Advisors LLC now owns 108,500 shares of the biotechnology company's stock worth $2,689,000 after acquiring an additional 3,500 shares during the last quarter. Institutional investors and hedge funds own 32.46% of the company's stock.

About Galapagos

(Get Free Report

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.

See Also

Analyst Recommendations for Galapagos (NASDAQ:GLPG)

Should you invest $1,000 in Galapagos right now?

Before you consider Galapagos, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Galapagos wasn't on the list.

While Galapagos currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Why Whitestone REIT is Outperforming in 2024: 35% Growth & Monthly Dividends
Why SoundHound Stock Dip Could Mean Big Gains for 2025 Investors
Nintendo Stock: Buy Before the 2025 Switch Platform Hits!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines